Document is current
Any future updates will be listed below
-
Authors
Funck-Brentano, Christian https://orcid.org/0000-0003-0406-5189
Ouologuem, Nouhoum
Duparc, Stephan
Felices, Mathieu
Sirima, Sodiomon B.
Sagara, Issaka
Soulama, Issiaka
Ouedraogo, Jean-Bosco
Beavogui, Abdoul H.
Borghini-Fuhrer, Isabelle
Khan, Yasmin
Djimdé, Abdoulaye A.
Voiriot, Pascal
-
Funding
Funding for this research was provided by:
This study was co-funded by the European & Developing Countries Clinical Trials Partnership, The Hague, The Netherlands and Medicines for Malaria Venture, Geneva, Switzerland.
- License Information
-
More Information
Article History
Received: 17 May 2018
Accepted: 4 December 2018
First Online: 29 January 2019
Competing Interests
: This study was co-funded by the European & Developing Countries Clinical Trials Partnership, The Hague, The Netherlands and Medicines for Malaria Venture, Geneva, Switzerland. C.F.-B. received fees as a safety consultant on several antimalarial drugs developed by MMV. S.D. and I.B.-F. are full time employees at Medicines for Malaria Venture. M.F. received grants from Banook group/Cardiabase, during the conduct of the study. Y.K. and P.V. received grants from MMV during the conduct of the study. Other authors have declared no conflict of interest.
